Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Daily news and press releases about Healthcare

older | 1 | .... | 1100 | 1101 | (Page 1102) | 1103 | 1104 | .... | 1118 | newer

    0 0

     



    (EMAILWIRE.COM, November 26, 2018 ) Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)-Pipeline Review, H2 2018SummaryTyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2-Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)-Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 4, 1, 7 and 3 respectively.


    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012318856/sample

    Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Cardiovascular, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myelofibrosis, Alopecia, Atopic Dermatitis (Atopic Eczema), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hematological Tumor, Leukemias, Myeloproliferative Disorders, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Asthma, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Leukemia, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Ulcerative Colitis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration. Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.



    Get Intresting Discount: https://www.reportsweb.com/inquiry&RW00012318856/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope-The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)-The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities -The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects -The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type -The report summarizes all the dormant and discontinued pipeline projects -The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeuticsReasons to buy-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage -Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)-Identify the use of drugs for target identification and drug repurposing-Identify potential new clients or partners in the target demographic-Develop strategic initiatives by understanding the focus areas of leading companies -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics-Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012318856/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 26, 2018 ) Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D-Pipeline Review, H2 2018, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

    Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.


    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012283654/sample



    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

    Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.



    Get Intresting Discount: https://www.reportsweb.com/inquiry&RW00012283654/discount



    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
    -The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283654/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 26, 2018 ) Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2018

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2018, provides an overview of the Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline landscape.

    Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.



    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012283655/sample


    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 19 and 5 molecules, respectively.

    Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


    Get Intresting Discount: https://www.reportsweb.com/inquiry&RW00012283655/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis) (Infectious Disease).
    -The pipeline guide reviews pipeline therapeutics for Chagas Disease (American Trypanosomiasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Chagas Disease (American Trypanosomiasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Chagas Disease (American Trypanosomiasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (American Trypanosomiasis) (Infectious Disease)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Chagas Disease (American Trypanosomiasis) (Infectious Disease).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283655/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 27, 2018 ) The bone cement market is estimated to grow at a CAGR of 5.4% during the forecast period from 2018 to 2025. The market for bone cement is projected to reach US$ 1,414.1 Mn in 2025. The market is witnessing a potential growth rate during the past few years and is expected to witness similar trend in the coming years. Factors such as, increasing prevalence of osteoporosis, growing demand for arthroplasty procedures, and growing geriatric population are primarily contributing to the growth of this market. Additionally, major manufacturers in the market are engaged in research and development activities to develop advanced products. Furthermore, rise in umber of osteoporosis cases and increase in number of bone disease cases are expected to boost the demand for bone cement in the coming years.

    According to a survey conducted by International Osteoporosis Foundation, around 15-30% male and 30-50% females are at a risk of suffering from osteoporotic fracture during their lifetime. Moreover, according to the International Osteoporosis Foundation, approximately one out of five men and one in every three women over the age of 50 would suffer from a fracture owing to osteoporosis. This is expected to stimulate the demand of bone cement market in the coming years. However, availability of substitutes can hamper the growth of this market at a certain extent.

    Request for a sample copy of this report @ http://bit.ly/2NWrSly

    Key Players:
    The major players operating in the bone cement market include DePuy Synthes, Zimmer Biomet, Stryker, Smith & Nephew, DJO Global, Arthrex, Inc., Tecres, Heraeus Holding, and Teknimed, Osteopoeriss LLC among others.

    The objective of this report is as follows:
    - To provide overview of the global Bone Cement market
    - To analyze and forecast the global Bone Cement market on the basis of type, application, and end user.
    - To provide market size and forecast till 2025 for overall Bone Cement market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America (SAM), which is later sub-segmented by respective countries
    - To evaluate market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend
    - To provide exhaustive PEST analysis for all five regions
    - To profiles key Bone Cement players influencing the market along with their SWOT analysis and market strategies.

    Check Discount : http://bit.ly/2NV5qcA

    Reason to Buy:
    Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Bone Cement market.
    -Highlights key business priorities in order to assist companies to realign their business strategies.
    -The key findings and recommendations highlight crucial progressive industry trends in the global Bone Cement market, thereby allowing players across the value chain to develop effective long-term strategies.
    -Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
    -Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
    -Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.



    Sameer Joshi
    +1-646-491-9876
    sam@theinsightpartners.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 27, 2018 ) North America region is expected to dominate the infection control market in the global arena due to growing emphasis on disinfection and food sterilization and rise in the number of surgeries. However, rising economies of China and India and enhanced healthcare infrastructure is expected to aid the growth of Asia Pacific infection control market in future.

    The report aims to provide an overview of global infection control market with detailed market segmentation by products, sterilization services, end user, and geography. The global infection control market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

    Request for a sample copy of this report @ http://bit.ly/2NTLjvf

    Key Players:
    Some of the key players influencing the market Ecolab, Cantel Medical, Advanced Sterilization Products (ASP), Sotera Health, STERIS plc, 3M, MMM Group Limited, Getinge AB, Halyard Worldwide, and Matachana Group among others.

    The objective of this report is as follows:
    - To provide overview of the global Infection Control market
    - To analyze and forecast the global Infection Control market on the basis of type, application, and end user.
    - To provide market size and forecast till 2025 for overall Infection Control market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America (SAM), which is later sub-segmented by respective countries
    - To evaluate market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend
    - To provide exhaustive PEST analysis for all five regions
    - To profiles key Infection Control players influencing the market along with their SWOT analysis and market strategies.

    Check Discount : http://bit.ly/2NW2Vqh

    Reason to Buy:
    Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the
    Infection Control market.
    -Highlights key business priorities in order to assist companies to realign their business strategies.
    -The key findings and recommendations highlight crucial progressive industry trends in the global Infection Control market, thereby allowing players across the value chain to develop effective long-term strategies.
    -Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
    -Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
    -Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.


    Sameer Joshi
    +1-646-491-9876
    sam@theinsightpartners.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 27, 2018 ) The report aims to provide an overview of global dental implants market with detailed market segmentation by material, procedure, end users, and geography. The global dental implants market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

    Increasing occurrence of periodontal diseases & dental caries, rising demand for cosmetic dentistry, and growing Edentulism problems globally, are the major drivers which are likely to propel the growth of dental implants market. Escalating demand of technological advancements, rising investments for CAD/CAM technologies in dental laboratories, and growing geriatric population are likely to add new opportunities for this market in the coming years.

    Request for a sample copy of this report @ http://bit.ly/2NV6yNm

    Key Players:
    Some of the key players influencing the market are Danaher, Zimmer Biomet, Camlog Biotechnologies AG, 3M, Institut Straumann AG, Dentsply Sirona, Avinent, Osstem Implants Co., Ltd., Dentium, and Henry Schein, Inc. among Others.

    The objective of this report is as follows:
    - To provide overview of the global Dental Implants market
    - To analyze and forecast the global Dental Implants market on the basis of type, application, and end user.
    - To provide market size and forecast till 2025 for overall Bone Cement market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America (SAM), which is later sub-segmented by respective countries
    - To evaluate market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend
    - To provide exhaustive PEST analysis for all five regions
    - To profiles key Dental Implants players influencing the market along with their SWOT analysis and market strategies.

    Check Discount : http://bit.ly/2NW3hND

    Reason to Buy:
    Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Dental Implants market.
    -Highlights key business priorities in order to assist companies to realign their business strategies.
    -The key findings and recommendations highlight crucial progressive industry trends in the global Dental Implants market, thereby allowing players across the value chain to develop effective long-term strategies.
    -Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
    -Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
    -Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.


    Sameer Joshi
    +1-646-491-9876
    sam@theinsightpartners.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 27, 2018 ) The report aims to provide an overview of global rehabilitation robots market with detailed market segmentation by type, mobility, and five major geographical regions. The global Rehabilitation robots market is expected to witness decent growth rate during the forecast period. Growing demand of rehabilitation robots from vulnerable people with elderly or disabilities will drive rehabilitation robots market in coming years.

    Rehabilitation robots are mechanically operated robots designed to improve movement in individuals with physical impaired functioning. High cost and limited functionality are few of the major drawbacks hindering the growth in adoption of rehabilitation robots, by majority of patients in some developed as well as developing countries.

    Request for a sample copy of this report @ http://bit.ly/2NWBSv5

    Key Players:
    Some of the leading players in rehabilitation robots market are AlterG, Inc., Ekso Bionics, Hocoma, Interactive Motion Technologies, Bioxtreme Robotics Rehabilitation, Instead Technologies, Kinestica, Kinetic Muscles, Kinova and MediTouch.

    The objective of this report is as follows:
    - To provide overview of the global rehabilitation robots market
    - To analyze and forecast the global rehabilitation robots market on the basis of type and mobility
    - To provide market size and forecast till 2025 for overall rehabilitation robots market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America (SAM), which is later sub-segmented by respective countries
    - To evaluate market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend
    - To provide exhaustive PEST analysis for all five regions
    - To profiles key rehabilitation robot players influencing the market along with their SWOT analysis and market strategies

    Check Discount : http://bit.ly/2NQD7vX

    Reason to Buy:
    Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the rehabilitation robots market.
    -Highlights key business priorities in order to assist companies to realign their business strategies.
    -The key findings and recommendations highlight crucial progressive industry trends in the global rehabilitation robots market, thereby allowing players across the value chain to develop effective long-term strategies.
    -Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
    -Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
    -Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.


    Sameer Joshi
    +1-646-491-9876
    sam@theinsightpartners.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 27, 2018 ) Technological advancements in drug delivery systems, mounting availability & affordability of these devices, and increase in the number of chronic diseases across the globe are the major drivers which are likely to boost the growth of drug delivery devices market. Growing geriatric population is likely to add new opportunities for this market in the coming years.

    The report aims to provide an overview of global drug delivery devices market with detailed market segmentation by type, application, and geography. The global drug delivery devices market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

    Request for a sample copy of this report @ http://bit.ly/2NVTJCg

    Key Players:
    Some of the key players influencing the market are 3M, Mylan N.V., Abbott, F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis, Antares Pharma, Baxter, Merck & Co., Inc., and Becton, Dickinson, and Company among others.

    The objective of this report is as follows:
    - To provide overview of the global Drug Delivery Devices market
    - To analyze and forecast the global Drug Delivery Devices market on the basis of types, distribution channel, and application.
    - To provide market size and forecast till 2025 for overall Drug Delivery Devices market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America (SAM), which is later sub-segmented by respective countries
    - To evaluate market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend
    - To provide exhaustive PEST analysis for all five regions
    - To profiles key Drug Delivery Devicest players influencing the market along with their SWOT analysis and market strategies.

    Check Discount : http://bit.ly/2NX4wwj

    Reason to Buy:
    Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Drug Delivery Devices market.
    -Highlights key business priorities in order to assist companies to realign their business strategies.
    -The key findings and recommendations highlight crucial progressive industry trends in the global Drug Delivery Devices market, thereby allowing players across the value chain to develop effective long-term strategies.
    -Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
    -Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
    -Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.


    Sameer Joshi
    +1-646-491-9876
    sam@theinsightpartners.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 28, 2018 ) Browse 109 market data Tables and 44 Figures spread through 181 Pages and in-depth TOC on "Healthcare Cloud Computing Market"
    https://www.marketsandmarkets.com/Market-Reports/cloud-computing-healthcare-market-347.html
    Early buyers will receive 10% customization on this report.

    The key factors driving the growth of this market include increasing adoption of big data, wearable devices, and IoT in healthcare; advantages of cloud usage (such as improved storage, flexibility, and scalability of data); implementation of healthcare reforms such as the Patient Protection and Affordable Care Act; and the dynamic nature of health benefit plan design.

    By application, the clinical information systems segment held the largest share of the market in 2018

    By application, the healthcare cloud computing market is segmented into clinical information systems and the nonclinical information systems. In 2018, the clinical information systems segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to rising prevalence of chronic disease and rising geriatric population leading to increasing volume of patient data.

    Download the PDF Brochure@
    https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=347

    By deployment model, the private cloud segment held the largest share of the market in 2018

    By application, the healthcare cloud computing market is segmented into private cloud, hybrid cloud, and public cloud models. In 2018, the private cloud segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to its higher adoption owing to its better security.

    By component, the services segment held the largest share of the market in 2018

    By component, the healthcare cloud computing market is segmented into software and services. In 2018, the services segment is expected to account for the largest share of the global market. The large share of this segment can be attributed to the recurring nature of services such as training and education, installation, software upgrades, consulting, and maintenance.

    North America to dominate the market in 2018

    In 2018, North America held the largest share of the healthcare cloud computing market, followed by Europe. Factors such as the increasing adoption of EHRs among medical professionals and active participation by private sector players in the development of the healthcare industry in that region are contributing to the dominant share of this region.

    Get the Sample Pages for More Details@
    https://www.marketsandmarkets.com/requestsampleNew.asp?id=347

    Some of the players in the global healthcare cloud computing market are CareCloud Corporation (US), ClearData Networks Inc. (US), Athenahealth (US), Cerner Corporation (US), Epic Systems Corporation (US), NextGen Healthcare (US), Carestream Corporation (Canada), Dell Inc. (US), DICOM Grid Inc. (US), INFINITT Healthcare (South Korea), Sectra AB (Sweden), Merge Healthcare Inc. (US), Siemens Healthineers (Germany), iTelagen Inc. (US), NTT DATA Corporation (Japan), Nuance Communications (US), and Ambra Health (US).

    About MarketsandMarkets™

    MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

    Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

    MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

    Contact:
    Mr. Shelly Singh
    MarketsandMarkets™ INC.
    630 Dundee Road
    Suite 430
    Northbrook, IL 60062
    USA : 1-888-600-6441
    sales@marketsandmarkets.com


    Mr. Shelly Singh
    1-888-600-6441
    sales@marketsandmarkets.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, November 28, 2018 ) The 'Global Sports and Fitness Apps Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Sports and Fitness Apps Market with a focus on the Chinese market. The report provides key statistics on the market status of the Sports and Fitness Apps manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail.

    Key Company Profile:
    • MapMyFitness Inc
    • Runtastic GmbH
    • FitnessKeeper Inc
    • Azumio Inc
    • Endomondo ApS
    • Wahoo
    • Garmin Ltd
    • Jawbone
    • Polar Electro
    • Pearsports etc.

    Request Free Sample of Sports and Fitness Apps market report at rnhttps://www.reportsnreports.com/contacts/requestsample.aspx?name=1616576

    The Sports and Fitness Apps Market report initially provides a basic overview of the industry that covers definition, applications and manufacturing technology post which the report explores into the international and Chinese players in the market. In this part, the report presents the company profile, product specifications, capacity, production value and 2013-2018 market shares for each company. The report depicts the global and Chinese market of Sports and Fitness Apps Industry including capacity, production, production value, cost and profit, supply and demand and Chinese import-export. The total market is further divided by company, by country, and by application or type for the competitive landscape analysis. The report also estimates 2018-2023 market development trends of Sports and Fitness Apps Industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Sports and Fitness Apps Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2013-2023 global and Chinese Sports and Fitness Apps Industry covering all important parameters.

    Request Here to Get Discount on This report https://www.reportsnreports.com/contacts/discount.aspx?name=1616576

    Table of Contents:
    Chapter One Introduction of Sports and Fitness Apps Industry
    1.1 Brief Introduction of Sports and Fitness Apps
    1.2 Development of Sports and Fitness Apps Industry
    1.3 Status of Sports and Fitness Apps Industry

    Chapter Two Manufacturing Technology of Sports and Fitness Apps
    2.1 Development of Sports and Fitness Apps Manufacturing Technology
    2.2 Analysis of Sports and Fitness Apps Manufacturing Technology
    2.3 Trends of Sports and Fitness Apps Manufacturing Technology

    Chapter Three Analysis of Global Key Players: MapMyFitness Inc, Runtastic GmbH, FitnessKeeper Inc, Azumio Inc, Endomondo ApS, Wahoo, Garmin Ltd, Jawbone, Polar Electro, Pearsports etc.

    Chapter Four 2013-2018 Global and Chinese Market of Sports and Fitness Apps
    4.1 2013-2018 Global Capacity, Production and Production Value of Sports and Fitness Apps Industry
    4.2 2013-2018 Global Cost and Profit of Sports and Fitness Apps Industry
    4.3 Market Comparison of Global and Chinese Sports and Fitness Apps Industry
    4.4 2013-2018 Global and Chinese Supply and Consumption of Sports and Fitness Apps
    4.5 2013-2018 Chinese Import and Export of Sports and Fitness Apps

    Purchase a Copy of this Report at https://www.reportsnreports.com/purchase.aspx?name=1616576

    Chapter Five Market Status of Sports and Fitness Apps Industry
    5.1 Market Competition of Sports and Fitness Apps Industry by Company
    5.2 Market Competition of Sports and Fitness Apps Industry by Country (USA, EU, Japan, Chinese etc.)
    5.3 Market Analysis of Sports and Fitness Apps Consumption by Application/Type

    Chapter Six 2018-2023 Market Forecast of Global and Chinese Sports and Fitness Apps Industry
    6.1 2018-2023 Global and Chinese Capacity, Production, and Production Value of Sports and Fitness Apps
    6.2 2018-2023 Sports and Fitness Apps Industry Cost and Profit Estimation
    6.3 2018-2023 Global and Chinese Market Share of Sports and Fitness Apps
    6.4 2018-2023 Global and Chinese Supply and Consumption of Sports and Fitness Apps
    6.5 2018-2023 Chinese Import and Export of Sports and Fitness Apps

    Chapter Seven Analysis of Sports and Fitness Apps Industry Chain
    7.1 Industry Chain Structure
    7.2 Upstream Raw Materials
    7.3 Downstream Industry

    Chapter Eight Global and Chinese Economic Impact on Sports and Fitness Apps Industry
    8.1 Global and Chinese Macroeconomic Environment Analysis
    8.1.1 Global Macroeconomic Analysis
    8.1.2 Chinese Macroeconomic Analysis
    8.2 Global and Chinese Macroeconomic Environment Development Trend
    8.2.1 Global Macroeconomic Outlook
    8.2.2 Chinese Macroeconomic Outlook
    8.3 Effects to Sports and Fitness Apps Industry

    Chapter Nine Market Dynamics of Sports and Fitness Apps Industry
    9.1 Sports and Fitness Apps Industry News
    9.2 Sports and Fitness Apps Industry Development Challenges
    9.3 Sports and Fitness Apps Industry Development Opportunities

    Chapter Ten Proposals for New Project
    10.1 Market Entry Strategies
    10.2 Countermeasures of Economic Impact
    10.3 Marketing Channels
    10.4 Feasibility Studies of New Project Investment

    Chapter Eleven Research Conclusions of Global and Chinese Sports and Fitness Apps Industry
    List of Tables and Figures
    Figure Sports and Fitness Apps Product Picture
    Table Development of Sports and Fitness Apps Manufacturing Technology
    Figure Manufacturing Process of Sports and Fitness Apps
    Table Trends of Sports and Fitness Apps Manufacturing Technology
    Figure Sports and Fitness Apps Product and Specifications
    Table 2013-2018 Sports and Fitness Apps Product Capacity, Production, and Production Value etc. List
    Figure 2013-2018 Sports and Fitness Apps Capacity Production and Growth Rate
    Figure 2013-2018 Sports and Fitness Apps Production Global Market Share
    Figure Sports and Fitness Apps Product and Specifications
    Table 2013-2018 Sports and Fitness Apps Product Capacity, Production, and Production Value etc. List
    Figure 2013-2018 Sports and Fitness Apps Capacity Production and Growth Rate
    Figure 2013-2018 Sports and Fitness Apps Production Global Market Share
    Figure Sports and Fitness Apps Product and Specifications
    More list of tables and figures available in the report.

    About Us:
    ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Feel free to Call us at +1 888 391 5441 or Email us at sales@reportsandreports.com


    Hrishikesh Patwardhan
    + 18883915441
    sales@reportsandreports.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, November 28, 2018 ) The global market size of Health Functional Food Market is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023.

    Major Players: Nestle, Cargill, ADM, Danone, Unilever, Coca Cola, Bunge, Barry Callebaut, Amway, Herbalife Nutrition, Oriflame Holdings, USANA Health Sciences et al.

    Request a Sample Report :- https://www.researchreportsinc.com/sample-request?id=222930 .

    The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

    There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment.

    For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023.

    This report covers following regions:
    • North America
    • South America
    • Asia & Pacific
    • Europe
    • MEA (Middle East and Africa)

    Grab Upto 30% Discount at :- https://www.researchreportsinc.com/check-discount?id=222930 .

    For end use/application segment, this report focuses on the status and outlook for key applications. End users also can be listed.

    Furthermore, years considered for the study are as follows:
    Historical year – 2013
    Base year – 2018
    Forecast period – 2018 to 2023.
    For competitor segment, the report includes global key players of Health Functional Food solutions as well as some small players.

    The information for each competitor includes:
    • Company Profile
    • Main Business Information
    • SWOT Analysis
    • Sales, Revenue, Price and Gross Margin
    • Market Share


    Have Any Query? Ask Our Experts at :- https://researchreportsinc.com/enquiry?id=222930 .

    TABLE OF CONTENTS-
    Chapter 1 Executive Summary
    Chapter 2 Abbreviation and Acronyms
    Chapter 3 Preface
    Chapter 4 Market Landscape
    Chapter 5 Market Trend Analysis
    Chapter 6 Chain Analysis
    Chapter 7 Latest Market Dynamics
    Chapter 8 Trading Analysis
    Chapter 9 Historical and Current Health Functional Food solutions Market in North America (2013-2018)
    Chapter 10 Historical and Current Health Functional Food solutions Market in South America (2013-2018)
    Chapter 11 Historical and Current Health Functional Food solutions Market in Asia & Pacific (2013-2018)
    Chapter 12 Historical and Current Health Functional Food solutions Market in Europe (2013-2018)
    Chapter 13 Historical and Current Health Functional Food solutions Market in MEA (2013-2018)
    Chapter 14 Summary for Global Health Functional Food solutions Market (2013-2018)
    Chapter 15 Global Health Functional Food solutions Market Forecast (2019-2023
    Chapter 16 Company Profile (Nestle, Cargill, ADM, Danone, Unilever, Coca Cola, Bunge, Barry Callebaut, Amway, Herbalife Nutrition, Oriflame Holdings, USANA Health Sciences et al.)

    We also can offer customized report to fulfill special requirements of our clients.

    Purchase this Premium Report at :- https://researchreportsinc.com/checkout/?add-to-cart=222930&&attribute_pa_choose-license=single-user&&quantity=1 .

    Contact Us-
    David
    (Sales Manager)
    US / Canada Toll Free: +1-855-419-2424
    UK: +44-0-330-808-7757
    Website - https://researchreportsinc.com
    Email - sales@researchreportsinc.com


    Shubham Goel
    8554192424
    pressrelease@researchreportsinc.com

    Source: EmailWire.Com

    0 0

     

    Fact.MR




    (EMAILWIRE.COM, November 28, 2018 ) An up-to-date research report has been disclosed by Fact.MR highlighting the titled “Ovarian Cancer Diagnostics Market Insights, Trends & Future Development Status Recorded during 2017-2022” which delivers an outlook of current market value as well as the expected forecast including Rate on Investment (ROI) together with growing CAGR of 8.7% during 2017-2022. The Report Studies the Ovarian Cancer Diagnostics Market Worldwide, especially in North America, Europe, Southeast Asia, India and Other Regions with production, size, growth, revenue, consumption, import and export in these regions.

    Request Here for Free Sample of Global Market Research Report Now - https://www.factmr.com/connectus/sample?flag=S&rep_id=51

    Ovarian cancer is developed by uncontrollable growth of cells in ovaries. Made up of three different types of cells, ovaries may develop three different types of tumors. Majority of these tumors are non-cancerous, which can be treated by removing either part of the ovary containing the tumor, or by removing the ovary itself.

    The American Cancer Society estimates that approx. 20,000 women will be diagnosed with ovarian cancer in the U.S. and more than 14,000 will lose their lives because of it in 2017 alone. In terms of deaths, this form of cancer ranks fifth and it led to more deaths than any other female reproductive system form of cancer. The chance of a women developing ovarian cancer during her life is 1 in 75 and the chance of her dying is 1 in 100. It is mainly seen in older women above the age of 63 years. Even though the rate at which women have been diagnosed with ovarian cancer has been falling, it is still a public health menace that needs to be tackled effectively. This is where the ovarian cancer diagnostics market can play a crucial role. The global ovarian cancer diagnostics market is predicted to grow with a CAGR of 8.7% and be worth nearly US$ 1 billion in 2022, from less than US$ 640 million in 2017.

    Epithelial Tumours Segment larger than the other two combined

    The Epithelial Tumours Segment is anticipated to grow to almost US $ 880 million by the end of the forecast period and it already accounts for an 11% revenue share in 2017 itself.  North America alone represents almost 2/5th of the market and it should touch US$ 330 million by the end of 2022. The germ cell carcinoma tumours segment is much smaller by comparison and is only poised to be a US$ 50 million market by the end of the five year study. Even the stromal carcinoma tumours segment is marginal at best when contrasted with epithelial tumours in the ovarian cancer diagnostics market. The stromal carcinoma tumours segment is likely to be valued at only US$ 28 million in 2017.

    Browse Market Report with TOC Here - https://www.factmr.com/report/51/ovarian-cancer-diagnostics-market

    The hospital associated lab segment is expected to record a CAGR of 7.8% from 2017-2022 and rise from just under $300 million in 2017 to roughly US$ 440 million in 2022. Independent diagnostic labs are the second most important segment in the ovarian cancer diagnostics market and are estimated to be worth US$ 161 million in 2017. While North America might account for the largest contribution, Europe should record a higher CAGR of 9.5% making it more attractive to target in the long term.

    Focus on CA 125 test segment in the ovarian cancer diagnostics market

    The CA 125 test segment could be worth roughly US$ 440 million in 2022 and some key stakeholders may decide to focus on this lucrative test over all other available alternatives in the ovarian cancer diagnostics market. However, the HER 2 segment also accounts for a 3.1% revenue share in 2017 and it would be unwise to do so. On the other hand, the BRCA segment in North America alone could grow with a CAGR of 8.3% for the period 2017-2022, making it imperative for companies to hedge their bets in the ovarian cancer diagnostics market.

    Competition Tracking

    The report has also profiled leading players in the global market for ovarian cancer diagnostics, which include Quest Diagnostics Incorporated, Myriad Genetics Inc., AstraZeneca plc., Epigenomics AG, Illumina, Inc., Bio-Rad Laboratories, Inc., Siemens AG, Thermo Fisher Scientific Inc., Roche Holding AG., and Abbott Laboratories.

    Buy Hassle Free Global Market Research Report Here - https://www.factmr.com/checkout/51/S

    About Fact.MR

    Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

    Contact Us

    Fact.MR
    11140 Rockville Pike
    Suite 400, Rockville, MD 20852
    United States
    Email: sales@factmr.com
    Web: https://www.factmr.com/
    Blog: https://factmrblog.com/


    James Hilton
    +353-1-6111-593
    info@factmr.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 28, 2018 ) Contraceptive rings are smooth, flexible round shaped plastic rings which are meant to insert into vagina to on first day woman’s menstrual cycle to prevent possible pregnancy. When contraceptive rings are placed into the vagina it releases two hormones named estrogen and progestogen which are similar to natural hormones released by the body and which are also used in the contraceptive pills. Contraceptive rings release continuous dose of these hormones into the blood which prevents the release of an egg by ovaries each month and hence preventing the pregnancy. When contraceptive ring is inserted, it is left inside vagina for 21 days and after that removed for seven days. During the seven days of contraceptive rings free interval, it still provides contraceptive effect preventing the possible pregnancy. After contraceptive rings free interval, the new contraceptive ring is placed.

    Contraceptive rings are most effective when used perfectly. Contraceptive rings are 99% effective when used correctly and with typical use they are 91% effective. Contraceptive rings are effective way to prevent pregnancy without any adverse effects. Once the contraceptive ring is inserted, it does not interfere with the sexual intercourse or doesn’t impart the sense of uneasiness.

    Contraceptive Rings Market: Drivers and Restraints

    Globally increasing demand for contraceptives to prevent unwanted pregnancy fuelling the growth of Contraceptive Rings Market. Unplanned pregnancy adversely affects mental health, personal and professional life as well and hence increasing demand for effective but long lasting measures to prevent pregnancy further drive the growth of contraceptive rings market. Ease of use of contraceptive rings, long lasting effectivity after using it and no requirement of daily attention complies with the consumer’s expectations driving the growth of contraceptive rings market. Contraceptive rings works even in mild sickness such as vomiting or diarrhoea, since one cannot take pills while having mild sickness contraceptive rings have added advantage and further driving the growth of market. Once inserted contraceptive rings prevents possible pregnancy for a month and hence provides relief from frequent administration like pills.

    Click here to subscribe Sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1770 

    Contraceptive rings may make periods more regular, decrease menstrual pain and improve premenstrual symptoms, these are added advantages with usage of contraceptive rings, contributing to market growth. Contraceptive rings are comparatively cheap and hence provides economical option to prevent unwanted pregnancy. The high success rate of contraceptive rings when used correctly further driving the growth of the market. Various public educational programs by government to increase awareness about birth control measures further expected to drive the growth of contraceptive rings market. Contraceptive rings has no major side effects and hence regarded as safe for usage, helping to drive the market growth. Whereas, woman who smoke and are more than 35 years of age may not use the contraceptive rings may hamper the growth of market. Contraceptive rings may not be suitable for persons who have blood clot in vein, high blood pressure, migraine, diabetes, overweight person, etc. hampering the growth of contraceptive rings market.

    Contraceptive Rings Market: Segmentation

    Global contraceptive rings market is segmented on the basis of product type, by distribution channel and by region

    Based on product type contraceptive rings market is segmented as:

    Etonogestrel/Ethinyl estradiol (ENG/EE) contraceptive rings
    Estradiol contraceptive rings
    Progesterone contraceptives rings
    Segesterone acetate/Ethinyl estradiol (SA/EE) contraceptive rings
    Based on the distribution channel contraceptive rings market is segmented as:

    Retail Pharmacies
    Hospital Pharmacies
    Clinics
    Others
    Contraceptive Rings Market: Overview

    Global contraceptive rings market is expected a steady growth due to increasing demand for birth control measures. The global contraceptive rings market is segmented based on the product type, distribution channel and region. By product type contraceptive rings market is expected to be dominated by etonogestrel/Ethinyl estradiol rings due to more efficacy. By distribution channel contraceptive rings market is expected to be dominated by retail pharmacies due to higher consumer convenience.

    Request/View TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=1770 

    Contraceptive Rings Market: Regional Outlook

    North America expected to dominate the contraceptive rings market followed by Europe due higher awareness and increasing adoption of contraceptive rings. Asia-Pacific is emerging contraceptive rings market due to emerging economies like India and China with increasing awareness about birth control measures in general population. Latin America is expected to witness steady growth due to increasing adoption of contraceptive rings as a birth control option. Middle East and Africa remains least lucrative market due to least adoption of contraceptive rings.

    Contraceptive Rings Market: Key Players

    Examples of some of the market participants in the global contraceptive rings market identified are:

    QPharma AB, Merck Sharp & Dohme B.V., Pfizer Inc., Laboratorios Andromaco SA, Janssen Pharmaceutical, Allergan plc and others.

    The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

    The report covers exhaustive analysis on:

    Market Segments
    Market Dynamics
    Market Size
    Supply & Demand
    Current Trends/Issues/Challenges
    Competition & Companies involved
    Technology
    Value Chain
    Regional analysis includes

    North America (U.S., Canada)
    Latin America (Mexico, Brazil)
    Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
    Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
    Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
    Japan
    Middle East and Africa (GCC, S. Africa, Rest Of MEA)
    Report Highlights:

    Detailed overview of parent market
    Changing market dynamics in the industry
    In-depth market segmentation
    Historical, current and projected market size in terms of volume and value
    Recent industry trends and developments
    Competitive landscape
    Strategies of key players and products offered
    Potential and niche segments, geographical regions exhibiting promising growth
    A neutral perspective on market performance
    Must-have information for market players to sustain and enhance their market footprint

    Report Analysis@ https://www.factmr.com/report/1770/contraceptive-rings-market 


    James Hilton
    +353-1-6111-593
    info@factmr.com

    Source: EmailWire.Com

    0 0

     

    Fact.MR




    (EMAILWIRE.COM, November 28, 2018 ) In order to study the various trends and patterns prevailing in the concerned global market, Fact.MR has included the latest Forecast report on Patient Positioning Market to its vast database. This study offers statistics about the prime regions and applications operating in the Patient Positioning Market, along with their market production, consumption, revenue, upcoming industry trends and future market share details. Further, the accomplished report also anticipates that the concerned market would grow at a constructive CAGR until 2022.

    Request for Free Sample Report of Described Market from Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=52

    Patient positioning can be defined as methods in which patients are positioned on beds during medical operations. Appropriate ventilation, anesthesia management, physiologic safety of patients, optimal exposure to surgical site, and maintaining the patient’s dignity by controlling undue exposure of body parts are observed as the key fundamentals of patient positioning.

    Surgical Tables Have the Largest Revenue Share Contribution

    The surgical tables segment accounted for 27% revenue share in the patient positioning systems market in the year 2017 which was higher than the 19% revenue share of tables segment. The surgical tables segment is poised to grow to almost half a billion by the end of 2022.

    Lesser Opportunity in Radiolucent Imaging and Examination Tables

    Radiolucent imaging is estimated to be a little over US$ 360 million by end 2022 and is on track to witness a steady CAGR of over 6%. North America accounts for approx. 40% of the radiolucent segment, and it is highly likely to retain this share for the rest of the study period. With respect to examination tables, a market opportunity of under US$ 200 million in 2017 might not seem very attractive initially but a CAGR of 5.2% for the five year period could be enough to sway major players to focus on this segment in the patient positioning systems market. The companies would be recommended to target Europe owing to the potential of emerging opportunities during the forecast period.

    Accessories and 'Other' Patient Positioning Systems Niche Segments

    With a revenue share of 12% and 7.7% in Accessories and Other patient positioning systems respectively, the two are undoubtedly niche segments in the patient positioning systems market. However, it would be unwise to ignore them entirely and manufacturers could focus on targeting North America in both cases as the region can present a significantly large market opportunity.

    You can Access Complete Factors of Market Report In-Depth Here - https://www.factmr.com/report/52/patient-positioning-market

    The combined market value of the two segments in North America in the year 2017 could easily exceed US$ 100 million which manufacturers should take cognizance of while devising their investment plans. In both cases, North America alone accounts for roughly 2/5th of the patient positioning systems market.

    Ambulatory Surgical and Global Diagnostic Centres Remain Lucrative

    The market opportunity that exists in the ambulatory surgical centres and global diagnostic centres is quite similar. Ambulatory surgical centres were worth just over US$ 330 million in 2017 and may grow with a CAGR of 7.3% from 2017-2022. On the other hand, global diagnostic centres may near a value of half a billion dollars by the end of the forecast period which would be equal to a revenue share of 27%. Europe and North America dominate the global diagnostics centre segment of the patient positioning systems market as they comprise more than half the market opportunity.

    Competition Tracking

    The report has also outlined the competitive landscape of global market for patient positioning systems, which includes Mizuho OSI, LEONI AG, C-RAD, Elekta AB(publ), Skytron, Span-America Medical Systems, Inc., STERIS plc., Stryker Corporation, and Hill-Rom, Inc.

    Grab Customized Market Report from Here - https://www.factmr.com/checkout/52/S

    About Fact.MR

    Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

    Contact Us

    Fact.MR
    11140 Rockville Pike
    Suite 400, Rockville, MD 20852
    United States
    Email: sales@factmr.com
    Web: https://www.factmr.com/
    Blog: https://factmrblog.com/


    James Hilton
    +353-1-6111-593
    info@factmr.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 28, 2018 ) The diagnosis and treatment of diseases occurring in upper air passages and ENT organs require thorough attention. The growing need for the usage of qualitative modern equipment to perform ENT procedures as well as the need for improved accessibility of doctor’s instruments to inspect a large patient pool plays a fundamental role in driving the demand for ENT workstations in the market. The usage of ENT workstations in ENT clinics and hospitals helps reduce labour intensity, thereby increasing the work efficiency of the physician. To upgrade the workstation of an otolaryngologist or an ENT specialist, specialised ENT workstations are being installed by major companies in several clinics. The work of an ENT specialist can be optimised by installing ENT workstations as they offer a wide range of functions to make the environment safe and technically upgraded for patients as well as doctors.

    The upgraded multiple-functionality ENT workstation, available through direct sales and equipment manufacturers, is mostly preferred by medical professionals over single ENT workstations with single functionality. The new ENT workstations design consists of various new features to provide support to multiple users if required. Features, such as integral ENT diagnosis & treatment equipment, higher defined endoscopic display, impressively clean view box, UV steriliser, PC installed and a much clearer microscopic display, are some of the high-end qualities that drive the demand for these ENT workstations in hospitals and multispecialty clinics.

    ENT workstations, such as the fixed ENT workstation and portable ENT workstation, are commercially available in distinct modalities. A wide range of portable ENT workstations are highly in demand, particularly for ENT clinics due to their easy handling. The standard ENT workstation is made using high-quality, electrolytically galvanised sheet steel and is a mobile ENT unit with a stainless steel base. The upgraded workstation is equipped with an electronic operating and display system along with a user-friendly glass display. With the growing incidence of ear, nasal and throat infections, there is an urgent need to boost the number of ENT clinics and hospitals where ENT treatments can be offered. The major potential end-users of the ENT workstation market, where they are highly in demand and generate significant revenues, include hospitals, ENT clinics and others.

    Click here to subscribe Sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1769 

    ENT Workstation Market: Drivers and Restraints

    The growing demand for ENT workstations indicated for ENT procedure, which are capable of offering a protective environment to the patient and easy accessibility of tools to the doctor, is expected to be a major factor driving the ENT workstation market over the forecast period. Moreover, the advantages offered by upgraded ENT workstations, such as the ready availability of cleaned and sterilised items required for ENT treatment, is expected to drive the revenue of the global ENT workstation market. In addition, the installation of medical diagnostic imaging instruments on the workstation includes personal computers, a slim x-ray view box, endoscopic display and a patient LCD monitor, and this is expected to generate high demand for ENT workstations. Growth in the global geriatric population, which leads to the increased prevalence of age-related disorders, mostly hearing loss & degraded functioning level of ENT, coupled with the presence of a well-established healthcare infrastructure in the developed regions, is estimated to boost the demand for ENT workstations from end-use facilities, thereby generating stiff competition among domestic players to meet the demand for ENT workstations from hospitals and ENT clinics.

    ENT Workstation Market: Segmentation

    The global ENT workstation market has been segmented on the basis of product type, end user and geography.

    Based on product type, the global ENT Workstation market is segmented as:

    Fixed ENT Workstation
    Portable ENT Workstation
    Based on end user, the global ENT Workstation market is segmented as:

    Hospitals
    ENT Clinics
    Others
    ENT Workstation Market: Overview

    The global ENT workstation market is expected to register a significant growth rate over the forecast period due to the introduction of technologically upgraded ENT workstations that are capable of performing multiple functions. Significant investments to introduce innovative products in the ENT workstation market to capitalise on the opportunities in the untapped markets is also expected to drive the revenue generation of the ENT workstation market. Different types of ENT workstations are being introduced in the ENT workstation market by leading players such as ATMOS MedizinTechnik GmbH & Co. KG, dantschke Medizintechnik GmbH & Co. KG and Entermed. Owing to the high competition among local and regional players of the ENT workstation market, the companies are adopting pricing strategies to attain a strong foothold. Among the product type, the portable ENT segment is expected to lead the global ENT workstation market over the forecast period. Specialty clinics, followed by hospitals, are expected to contribute a high revenue share to the global ENT workstation market on the account of the high demand for ENT workstations generated from ENT specialist clinics.

    Request/View TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=1769 

    ENT Workstation Market: Regional Outlook

    Geographically, the global ENT workstation market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is projected to hold the largest share of the global ENT workstation market primarily due to the presence of a large number of specialty clinics and advanced healthcare infrastructure. However, Asia-Pacific is expected to register the fastest growth in revenue generation for the ENT workstation market on the account of the high presence of local manufacturers in countries such as Japan, China and India. However, Latin America, owing to the presence of a less stringent regulatory framework and upgraded medical infrastructure, is expected to experience high demand for ENT workstations during the forecast period.

    ENT Workstation Market: Key Players

    The global ENT workstation market is highly fragmented owing to the strong footprints of domestic manufacturers. Some of the key players operating in the global ENT workstation market are ATMOS MedizinTechnik GmbH & Co. KG, dantschke Medizintechnik GmbH & Co. KG, Entermed, MEDSTAR Co., Ltd., Foshan Gladent Medical, Global Surgical Corporation, MS Westfalia and G. Heinemann Medizintechnik GmbH.

    The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

    The report covers exhaustive analysis on:

    Market Segments
    Market Dynamics
    Market Size
    Supply & Demand
    Current Trends/Issues/Challenges
    Competition & Companies involved
    Technology
    Value Chain
    Regional analysis includes

    North America (U.S., Canada)
    Latin America (Mexico, Brazil, Argentina, Chile, Peru, and Rest of Latin America)
    Europe [EU -4 (Germany, France, Italy, Spain), BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
    CIS & Russia
    Japan
    APEJ (Greater China, India, S. Korea, ASEAN Countries and Rest of APEJ)
    Middle East & Africa (GCC Countries, Turkey, Iran, Israel, South Africa, Rest of MEA)
    Report Highlights:

    Detailed overview of parent market
    Changing market dynamics in the industry
    In-depth market segmentation
    Historical, current and projected market size in terms of volume and value
    Recent industry trends and developments
    Competitive landscape
    Strategies of key players and products offered
    Potential and niche segments, geographical regions exhibiting promising growth
    A neutral perspective on market performance
    Must-have information for market players to sustain and enhance their market footprint.
    Report Analysis@ https://www.factmr.com/report/1769/ent-workstation-market 


    James Hilton
    +353-1-6111-593
    info@factmr.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 28, 2018 ) Eye shields are advised for use in the eye while a periorbital surgery to avoid any injury to the globe. Ophthalmic eye shields are used for postoperative ocular protection. Ophthalmic eye shields protect the cornea and retina while any eye surgery or laser treatment. Ophthalmic eye shields are highly preferred for cataract surgeries in the elder population and blepharitis correction especially for children. According to WHO, The World Health Organization, there are approximately 18 million people who are bilaterally blind with cataract worldwide. This represents almost half of the global cases of blindness in the world. Cataract is the leading cause of blindness and is one of the most important causes of visual impairment globally.  Rising cases of cataract because of rise in geriatric population is the major factor leading to the need of ophthalmic eye shields.

    Ophthalmic Eye Shield Market: Drivers

    Growing incidence of eye diseases and certain eye related ailments are driving the market for ophthalmic eye shield globally. Increase in prevalence and incidence cases for age-dependant macular degeneration, cataract, color blindness correction, macular edema and glaucoma are expected to drive the market for ophthalmic eye shields over the forecast period. Rise in geriatric population is also driving the market for ophthalmic eye shield owing it increased population of people undergoing eye correction procedures. However, certain risk of complications like infections or allergies because of the eye shield material or the lubricant used by the doctor might hinder the market growth for ophthalmic eye shield over the forecast period. Ophthalmic eye shields still being debated on regarding having a comfortable surgery with or without them. This might also hinder the market growth for ophthalmic eye shields over the forecast period.

    Click here to subscribe Sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1768 

    Ophthalmic Eye Shield Market: Segmentation

    Tentatively, the global Ophthalmic Eye Shield Market can be segmented on the basis of material type, sterility, usability, size, end users and geography.

    Based on Material type, the global Ophthalmic Eye Shield Market is segmented as:

    Aluminium Ophthalmic Eye Shield
    Stainless Steel Ophthalmic Eye Shield
    Plastic Ophthalmic Eye Shield
    Others
    Based on Usability, the global Ophthalmic Eye Shield Market is segmented as:

    Disposable Ophthalmic Eye Shield
    Reusable Ophthalmic Eye Shield
    Based on Size, the global Ophthalmic Eye Shield Market is segmented as:

    Adult sized Ophthalmic Eye Shield
    Children sized Ophthalmic Eye Shield
    Based on end users, the global Ophthalmic Eye Shield Market is segmented as:

    Hospitals
    Specialized Clinics
    Ophthalmology Centers
    Others
    Based on geography, the global Ophthalmic Eye Shield Market is segmented as:

    North America
    Latin America
    Europe
    CIS & Russia
    Japan
    APEJ
    Middle East & Africa
    Request/View TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=1768 

    Ophthalmic Eye Shield Market: Overview

    Ophthalmic Eye Shield market is highly driven by the disposable ophthalmic eye shield segment owing it to the lesser risk of infections involved with them. Sterilization methods vary with different sterile ophthalmic eye shield products. Use of ethylene oxide and use of steam and gas for sterilizing the ophthalmic eye shield is driving the sterile eye shield segment. Aluminium ophthalmic eye shields are highly preferred owing it to the lightweight and better shelf life involved. An upsurge in laser treatments and eye corrections is leading the ophthalmic eye shield market. Specialized Clinics and Ophthalmology Centers are mostly preferred for better eye treatments and thus, are expected to grow at a fast rate under the end user segment over the forecast period.

    Ophthalmic Eye Shield Market: Regional Outlook

    One of the vital factors which is driving the North America market for Ophthalmic Eye Shield is the growing awareness about the availability of Ophthalmic Eye Shield for treatment of various eye diseases and related ailments. North America’s ophthalmic eye shield market is also expected to grow at a fast rate owing it to good healthcare spending and healthcare infrastructure. China is one of the leading regions for ophthalmic eye shield market because of high cataract population and consistent rise in geriatric population. Blindness rate are highest in the region and thus, it is expected to be one of the largest market for ophthalmic eye shield.

    Ophthalmic Eye Shield Market: Key Players

    The major market participants operating in the global Ophthalmic Eye Shield Market are AJL OPHTHALMIC, S.A, Surgistar, Inc., FCI, Jardon Eye Prosthetics, BAUSCH & LOMB INCORPORATED, Gulden Ophthalmics, NanoVision, Dsa Exports and Univet. Companies are improving their product range by focusing on developing light weighted eye shields.

    The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

    The report covers exhaustive analysis on:

    Market Segments
    Market Dynamics
    Market Size
    Supply & Demand
    Current Trends/Issues/Challenges
    Competition & Companies involved
    Technology
    Value Chain
    Regional analysis includes

    North America (U.S., Canada)
    Latin America (Mexico, Brazil)
    Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
    Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
    Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
    Japan
    Middle East and Africa (GCC, S. Africa, Rest Of MEA)
    Report Highlights:

    Detailed overview of parent market
    Changing market dynamics in the industry
    In-depth market segmentation
    Historical, current and projected market size in terms of volume and value
    Recent industry trends and developments
    Competitive landscape
    Strategies of key players and products offered
    Potential and niche segments, geographical regions exhibiting promising growth
    A neutral perspective on market performance
    Must-have information for market players to sustain and enhance their market footprint.

    Report Analysis@ https://www.factmr.com/report/1768/ophthalmic-eye-shield-market 


    James Hilton
    +353-1-6111-593
    info@factmr.com

    Source: EmailWire.Com

    0 0

     

    Fact.MR




    (EMAILWIRE.COM, November 28, 2018 ) According to Fact.MR’s recent report, the global market for speech generating devices is expected to register a staggering expansion at a CAGR of 12.2% during the forecast period 2017 to 2022. The report projects the Revenues from Global Speech Generating Devices Market to account for US$ 168.6 Mn in 2017; by 2022 this number is expected to reach nearly US$ 300 Mn.

    Speech Generating Devices (SGDs), an assistive technology, are electronic augmentative & alternative communication (AAC) systems enabling individuals with severe speech impairments to verbally communicate. Organization, content, and updating vocabulary of SGDs are influenced by numerous factors such as patient’s requirements, and contexts in which the devices will be utilized. Several input and display methods of SGDs are available, including fixed display, dynamic display, and talking keyboards, for users with varying speech disabilities.

    Request for Sample of this Global Market Research Report Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=53

    A number of developments in the electronic technology over the past decade have enabled the speech generating devices to be portable and comparatively more user interactive. Several variants of speech generating devices are available on the basis of text, symbol system, cognitive abilities, physical abilities, tongue switches, and eye tracking system. Expansion of the global market for speech generating devices is mainly attributed to advancements in technology and rising availability of user-friendly devices. The National Institute of Deafness & Other Communication Disorders (NIDCD) has anticipated that approximately 7.5 Mn population in the U.S. is affected with speech-related disorders.

    Market players in the global speech generating devices market are concentrating on enhancing touch-screen devices to offer users with easy navigation. These manufacturers are enabling speech generating devices to connect with smart phones. Owing to speech generating devices’ portable nature, adoption of these devices is witnessing an upsurge among patients affected with speech-related disorders. This is further expected to pave tremendous opportunities for players in the global speech generating devices market. However, factors such as high cost and low penetration of speech generating devices are expected to curb growth of the market.

    North America to Remain the Most Lucrative Market for Speech Generating Devices

    North America is estimated to remain the most lucrative region in the global market for speech generating devices, followed by Europe. In North America, sales of speech generating devices is expected to account for revenues worth US$ 126.7 Mn by 2022-end. Speech generating devices market in Asia Pacific excluding Japan (APEJ) is expected to register the fastest expansion through 2022.

    Request Global Market Report with TOC Here - https://www.factmr.com/report/53/speech-generating-devices-market

    By product type, synthesized speech devices are expected to remain preferred in the global market for speech generating devices, followed by picture communicators. Text-to-speech devices’ sales are expected to exhibit the highest CAGR through 2022.

    On the basis of display, even though speech generating devices with static display will remain sought-after, sales of speech generating devices with dynamic display will continue to exhibit a comparatively higher CAGR through 2022.

    Specialty clinics will remain dominant among distribution channels in the global speech generating devices market, witnessing expansion at the highest CAGR during the forecast period. Hospitals will remain the second most lucrative distribution channel for speech generating devices in the market, estimated to account for over US$ 100 Mn by 2022-end. Based on technology, manual segment will witness the largest adoption in the market, followed by eye tracking and head tracking technology-based speech generating devices.

    Competition Tracking

    Fact.MR’ report profiles key players in the global speech generating devices market, which include Abilia Toby Churchill Limited, AMDi, Saltillo Corporation, Zyteq Pty Ltd., Tobii Dynavox, Prentke Romich Company, Inc., Lingraphica, Textspeak, and Zygo USA.

    To Buy Global Market Research Report, Go with this Link - https://www.factmr.com/checkout/53/S

    About Fact.MR

    Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

    Contact Us

    Fact.MR
    11140 Rockville Pike
    Suite 400, Rockville, MD 20852
    United States
    Email: sales@factmr.com
    Web: https://www.factmr.com/
    Blog: https://factmrblog.com/


    James Hilton
    +353-1-6111-593
    info@factmr.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, November 28, 2018 ) “Global Nuclear Medicine-Radiopharmaceuticals Market 2018” report provides information on grasping newer technologies and recent development made in Nuclear Medicine-Radiopharmaceuticals & satisfies specialized and enterprise-wide statistical needs.

    This report studies the global market size of Nuclear Medicine/Radiopharmaceuticals in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Nuclear Medicine/Radiopharmaceuticals in these regions. This research report categorizes the global Nuclear Medicine/Radiopharmaceuticals market by players/brands, region, type, and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.

    Download Free PDF Sample of Global Nuclear Medicine-Radiopharmaceuticals Market 2018 report @ https://decisionmarketreports.com/request-sample?productID=858426

    Radiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged—for example, positron-emitting radiopharmaceuticals.

    The various contributors involved in the value chain of Nuclear Medicine/Radiopharmaceuticals include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Nuclear Medicine/Radiopharmaceuticals include
    China Isotope & Radiation
    Dongcheng
    Jaco
    Ciaeriar
    Advanced Molecular-imaging Solution
    Shanghai Atom Kexing

    Market Size Split by Type
    Diagnostic
    Therapeutic

    Market Size Split by Application
    Oncology
    Thyroid
    Cardiology

    Nuclear medicine is a medical specialty that allows modern diagnostics and treatments using radiopharmaceuticals original radiotracers. Radiopharmaceuticals are considered a special group of drugs and thus their preparation and use are regulated by a set of policies that have been adopted by individual member countries. In China, radioactive drug approval process is cumbersome, drug research and development cycle is too long and the high-end equipment of China mainly relies on imports, which restrict the development of nuclear medicine.

    In application, nuclear medicine/radiopharmaceuticals are for treatment oncology, thyroid, cardiology, and other diseases. The nuclear medicine/radiopharmaceuticals market is mainly driven by growing demand for treatment cardiology which accounts for nearly 42.19 % of total downstream consumption of Nuclear Medicine / Radiopharmaceuticals in China.

    In 2017, the global Nuclear Medicine/Radiopharmaceuticals market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Nuclear Medicine/Radiopharmaceuticals market based on company, product type, application, and key regions.

    Market size split by Region
    North America
    United States
    Canada
    Mexico
    Asia-Pacific
    China
    India
    Japan
    South Korea
    Australia
    Indonesia
    Singapore
    Malaysia
    Philippines
    Thailand
    Vietnam
    Europe
    Germany
    France
    UK
    Italy
    Spain
    Russia
    Central & South America
    Brazil
    Rest of Central & South America
    Middle East & Africa
    GCC Countries
    Turkey
    Egypt
    South Africa

    Access full report with TOC @ https://decisionmarketreports.com/market-reports/858426/global-nuclear-medicine-radiopharmaceuticals-market

    Table of Contents

    1 Study Coverage
    1.1 Nuclear Medicine/Radiopharmaceuticals Product
    1.2 Key Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
    1.4.1 Global Nuclear Medicine/Radiopharmaceuticals Market Size Growth Rate by Type
    1.4.2 Diagnostic
    1.4.3 Therapeutic
    1.5 Market by Application
    1.5.1 Global Nuclear Medicine/Radiopharmaceuticals Market Size Growth Rate by Application
    1.5.2 Oncology
    1.5.3 Thyroid
    1.5.4 Cardiology
    1.6 Study Objectives
    1.7 Years Considered

    2 Executive Summary
    2.1 Global Nuclear Medicine/Radiopharmaceuticals Market Size
    2.1.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue 2016-2025
    2.1.2 Global Nuclear Medicine/Radiopharmaceuticals Sales 2016-2025
    2.2 Nuclear Medicine/Radiopharmaceuticals Growth Rate by Regions
    2.2.1 Global Nuclear Medicine/Radiopharmaceuticals Sales by Regions
    2.2.2 Global Nuclear Medicine/Radiopharmaceuticals Revenue by Regions

    3 Breakdown Data by Manufacturers
    3.1 Nuclear Medicine/Radiopharmaceuticals Sales by Manufacturers
    3.1.1 Nuclear Medicine/Radiopharmaceuticals Sales by Manufacturers
    3.1.2 Nuclear Medicine/Radiopharmaceuticals Sales Market Share by Manufacturers
    3.1.3 Global Nuclear Medicine/Radiopharmaceuticals Market Concentration Ratio (CR5 and HHI)
    3.2 Nuclear Medicine/Radiopharmaceuticals Revenue by Manufacturers
    3.2.1 Nuclear Medicine/Radiopharmaceuticals Revenue by Manufacturers (2016-2018)
    3.2.2 Nuclear Medicine/Radiopharmaceuticals Revenue Share by Manufacturers (2016-2018)
    3.3 Nuclear Medicine/Radiopharmaceuticals Price by Manufacturers
    3.4 Nuclear Medicine/Radiopharmaceuticals Manufacturing Base Distribution, Product Types
    3.4.1 Nuclear Medicine/Radiopharmaceuticals Manufacturers Manufacturing Base Distribution, Headquarters
    3.4.2 Manufacturers Nuclear Medicine/Radiopharmaceuticals Product Category
    3.4.3 Date of International Manufacturers Enter into Nuclear Medicine/Radiopharmaceuticals Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type
    4.1 Global Nuclear Medicine/Radiopharmaceuticals Sales by Type
    4.2 Global Nuclear Medicine/Radiopharmaceuticals Revenue by Type
    4.3 Nuclear Medicine/Radiopharmaceuticals Price by Type

    5 Breakdown Data by Application
    5.1 Overview
    5.2 Global Nuclear Medicine/Radiopharmaceuticals Breakdown Data by Application

    6 North America
    6.1 North America Nuclear Medicine/Radiopharmaceuticals by Countries
    6.1.1 North America Nuclear Medicine/Radiopharmaceuticals Sales by Countries
    6.1.2 North America Nuclear Medicine/Radiopharmaceuticals Revenue by Countries
    6.1.3 United States
    6.1.4 Canada
    6.1.5 Mexico
    6.2 North America Nuclear Medicine/Radiopharmaceuticals by Type
    6.3 North America Nuclear Medicine/Radiopharmaceuticals by Application
    6.4 North America Nuclear Medicine/Radiopharmaceuticals by Company

    7 Europe
    7.1 Europe Nuclear Medicine/Radiopharmaceuticals by Countries
    7.1.1 Europe Nuclear Medicine/Radiopharmaceuticals Sales by Countries
    7.1.2 Europe Nuclear Medicine/Radiopharmaceuticals Revenue by Countries
    7.1.3 Germany
    7.1.4 France
    7.1.5 UK
    7.1.6 Italy
    7.1.7 Russia
    7.2 Europe Nuclear Medicine/Radiopharmaceuticals by Type
    7.3 Europe Nuclear Medicine/Radiopharmaceuticals by Application
    7.4 Europe Nuclear Medicine/Radiopharmaceuticals by Company

    8 Asia Pacific
    8.1 Asia Pacific Nuclear Medicine/Radiopharmaceuticals by Countries
    8.1.1 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Sales by Countries
    8.1.2 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Revenue by Countries
    8.1.3 China
    8.1.4 Japan
    8.1.5 Korea
    8.1.6 India
    8.1.7 Australia
    8.1.8 Indonesia
    8.1.9 Malaysia
    8.1.10 Philippines
    8.1.11 Thailand
    8.1.12 Vietnam
    8.1.13 Singapore
    8.2 Asia Pacific Nuclear Medicine/Radiopharmaceuticals by Type
    8.3 Asia Pacific Nuclear Medicine/Radiopharmaceuticals by Application
    8.4 Asia Pacific Nuclear Medicine/Radiopharmaceuticals by Company

    9 Central & South America
    9.1 Central & South America Nuclear Medicine/Radiopharmaceuticals by Countries
    9.1.1 Central & South America Nuclear Medicine/Radiopharmaceuticals Sales by Countries
    9.1.2 Central & South America Nuclear Medicine/Radiopharmaceuticals Revenue by Countries
    9.1.3 Brazil
    9.2 Central & South America Nuclear Medicine/Radiopharmaceuticals by Type
    9.3 Central & South America Nuclear Medicine/Radiopharmaceuticals by Application
    9.4 Central & South America Nuclear Medicine/Radiopharmaceuticals by Company

    10 Middle East and Africa
    10.1 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals by Countries
    10.1.1 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Sales by Countries
    10.1.2 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Revenue by Countries
    10.1.3 GCC Countries
    10.1.4 Turkey
    10.1.5 Egypt
    10.1.6 South Africa
    10.2 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals by Type
    10.3 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals by Application
    10.4 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals by Company

    11 Company Profiles
    11.1 China Isotope & Radiation
    11.1.1 China Isotope & Radiation Company Details
    11.1.2 Company Description
    11.1.3 Sales, Revenue and Gross Margin of Nuclear Medicine/Radiopharmaceuticals
    11.1.4 Nuclear Medicine/Radiopharmaceuticals Product Description
    11.1.5 Recent Development
    11.2 Dongcheng
    11.2.1 Dongcheng Company Details
    11.2.2 Company Description
    11.2.3 Sales, Revenue and Gross Margin of Nuclear Medicine/Radiopharmaceuticals
    11.2.4 Nuclear Medicine/Radiopharmaceuticals Product Description
    11.2.5 Recent Development
    11.3 Jaco
    11.3.1 Jaco Company Details
    11.3.2 Company Description
    11.3.3 Sales, Revenue and Gross Margin of Nuclear Medicine/Radiopharmaceuticals
    11.3.4 Nuclear Medicine/Radiopharmaceuticals Product Description
    11.3.5 Recent Development
    11.4 Ciaeriar
    11.4.1 Ciaeriar Company Details
    11.4.2 Company Description
    11.4.3 Sales, Revenue and Gross Margin of Nuclear Medicine/Radiopharmaceuticals
    11.4.4 Nuclear Medicine/Radiopharmaceuticals Product Description
    11.4.5 Recent Development
    11.5 Advanced Molecular-imaging Solution
    11.5.1 Advanced Molecular-imaging Solution Company Details
    11.5.2 Company Description
    11.5.3 Sales, Revenue and Gross Margin of Nuclear Medicine/Radiopharmaceuticals
    11.5.4 Nuclear Medicine/Radiopharmaceuticals Product Description
    11.5.5 Recent Development
    11.6 Shanghai Atom Kexing
    11.6.1 Shanghai Atom Kexing Company Details
    11.6.2 Company Description
    11.6.3 Sales, Revenue and Gross Margin of Nuclear Medicine/Radiopharmaceuticals
    11.6.4 Nuclear Medicine/Radiopharmaceuticals Product Description
    11.6.5 Recent Development

    12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    12.1 Market Opportunities and Drivers
    12.2 Market Challenges
    12.3 Market Risks/Restraints
    12.4 Key World Economic Indicators

    13 Value Chain and Sales Channels Analysis
    13.1 Value Chain Analysis
    13.1.1 Typical Suppliers of Key Nuclear Medicine/Radiopharmaceuticals Raw Material
    13.1.2 Nuclear Medicine/Radiopharmaceuticals Customers
    13.2 Sales Channels Analysis
    13.2.1 Sales Channels Analysis
    13.2.2 Distributors

    14 Research Findings and Conclusion

    15 Appendix
    15.1 Research Methodology
    15.1.1 Methodology/Research Approach
    15.1.1.1 Research Programs/Design
    15.1.1.2 Market Size Estimation
    15.1.1.3 Market Breakdown and Data Triangulation
    15.1.2 Data Source
    15.1.2.1 Secondary Sources
    15.1.2.2 Primary Sources
    15.2 Author Details
    15.3 Disclaimer

    Continued...

    About Decision Market Reports
    Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

    Contact Information:
    Gasper James,
    Decision Market Reports,
    304 S Jones Blvd,
    Las Vegas,
    NV 89107, USA
    Call: 1-800-526-8630 (Toll-Free)
    Email:sales@decisionmarketreports.com




    Gasper James
    +1-866-605-1052
    g.james @decisionmarketreports.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, November 28, 2018 ) “Global Natural Killer (NK) Cell Therapeutics Market 2018” report provides information on grasping newer technologies and recent development made in Natural Killer (NK) Cell Therapeutics & satisfies specialized and enterprise-wide statistical needs.

    This report studies the global market size of Natural Killer (NK) Cell Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Natural Killer (NK) Cell Therapeutics in these regions. This research report categorizes the global Natural Killer (NK) Cell Therapeutics market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.

    Download Free PDF Sample of Global Natural Killer (NK) Cell Therapeutics Market 2018 report @ https://decisionmarketreports.com/request-sample?productID=858438

    The various contributors involved in the value chain of Natural Killer (NK) Cell Therapeutics include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Natural Killer (NK) Cell Therapeutics include

    Chipscreen Biosciences (China)
    Affimed NV (Netherlands)
    Altor BioScience Corporation (USA)
    Innate Pharma SA (France)
    Takeda Pharmaceutical (Japan)
    Sorrento Therapeutics Inc. (USA)
    NantKwest Inc. (USA)
    Bristol-Myers Squibb (USA)
    NKT Therapeutics (USA)
    Market Size Split by Type

    Mogamulizumab
    Lorvotuzumab Mertansine
    Others
    Market Size Split by Application

    Cancer
    Cardiovascular Diseases
    Others
    Natural killer cells are a type of cytotoxic lymphocyte, which is a component of the innate immune system.
    In 2017, the global Natural Killer (NK) Cell Therapeutics market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Natural Killer (NK) Cell Therapeutics market based on company, product type, application and key regions.

    Access full report with TOC @ https://decisionmarketreports.com/market-reports/858438/global-natural-killer-nk-cell-therapeutics-market

    This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Natural Killer (NK) Cell Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

    Market size split by Region

    North America
    United States
    Canada
    Mexico
    Asia-Pacific
    China
    India
    Japan
    South Korea
    Australia
    Indonesia
    Singapore
    Malaysia
    Philippines
    Thailand
    Vietnam
    Europe
    Germany
    France
    UK
    Italy
    Spain
    Russia
    Central & South America
    Brazil
    Rest of Central & South America
    Middle East & Africa
    GCC Countries
    Turkey
    Egypt
    South Africa
    The study objectives of this report are:

    To study and analyze the global Natural Killer (NK) Cell Therapeutics market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
    To understand the structure of Natural Killer (NK) Cell Therapeutics market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    Focuses on the key global Natural Killer (NK) Cell Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
    To analyze the Natural Killer (NK) Cell Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
    To project the value and volume of Natural Killer (NK) Cell Therapeutics submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.
    Table of Contents

    1 Study Coverage
    1.1 Natural Killer (NK) Cell Therapeutics Product
    1.2 Key Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
    1.4.1 Global Natural Killer (NK) Cell Therapeutics Market Size Growth Rate by Type
    1.4.2 Mogamulizumab
    1.4.3 Lorvotuzumab Mertansine
    1.4.4 Others
    1.5 Market by Application
    1.5.1 Global Natural Killer (NK) Cell Therapeutics Market Size Growth Rate by Application
    1.5.2 Cancer
    1.5.3 Cardiovascular Diseases
    1.5.4 Others
    1.6 Study Objectives
    1.7 Years Considered

    2 Executive Summary
    2.1 Global Natural Killer (NK) Cell Therapeutics Market Size
    2.1.1 Global Natural Killer (NK) Cell Therapeutics Revenue 2016-2025
    2.1.2 Global Natural Killer (NK) Cell Therapeutics Sales 2016-2025
    2.2 Natural Killer (NK) Cell Therapeutics Growth Rate by Regions
    2.2.1 Global Natural Killer (NK) Cell Therapeutics Sales by Regions
    2.2.2 Global Natural Killer (NK) Cell Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers
    3.1 Natural Killer (NK) Cell Therapeutics Sales by Manufacturers
    3.1.1 Natural Killer (NK) Cell Therapeutics Sales by Manufacturers
    3.1.2 Natural Killer (NK) Cell Therapeutics Sales Market Share by Manufacturers
    3.1.3 Global Natural Killer (NK) Cell Therapeutics Market Concentration Ratio (CR5 and HHI)
    3.2 Natural Killer (NK) Cell Therapeutics Revenue by Manufacturers
    3.2.1 Natural Killer (NK) Cell Therapeutics Revenue by Manufacturers (2016-2018)
    3.2.2 Natural Killer (NK) Cell Therapeutics Revenue Share by Manufacturers (2016-2018)
    3.3 Natural Killer (NK) Cell Therapeutics Price by Manufacturers
    3.4 Natural Killer (NK) Cell Therapeutics Manufacturing Base Distribution, Product Types
    3.4.1 Natural Killer (NK) Cell Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
    3.4.2 Manufacturers Natural Killer (NK) Cell Therapeutics Product Category
    3.4.3 Date of International Manufacturers Enter into Natural Killer (NK) Cell Therapeutics Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type
    4.1 Global Natural Killer (NK) Cell Therapeutics Sales by Type
    4.2 Global Natural Killer (NK) Cell Therapeutics Revenue by Type
    4.3 Natural Killer (NK) Cell Therapeutics Price by Type

    5 Breakdown Data by Application
    5.1 Overview
    5.2 Global Natural Killer (NK) Cell Therapeutics Breakdown Data by Application

    6 North America
    6.1 North America Natural Killer (NK) Cell Therapeutics by Countries
    6.1.1 North America Natural Killer (NK) Cell Therapeutics Sales by Countries
    6.1.2 North America Natural Killer (NK) Cell Therapeutics Revenue by Countries
    6.1.3 United States
    6.1.4 Canada
    6.1.5 Mexico
    6.2 North America Natural Killer (NK) Cell Therapeutics by Type
    6.3 North America Natural Killer (NK) Cell Therapeutics by Application
    6.4 North America Natural Killer (NK) Cell Therapeutics by Company

    7 Europe
    7.1 Europe Natural Killer (NK) Cell Therapeutics by Countries
    7.1.1 Europe Natural Killer (NK) Cell Therapeutics Sales by Countries
    7.1.2 Europe Natural Killer (NK) Cell Therapeutics Revenue by Countries
    7.1.3 Germany
    7.1.4 France
    7.1.5 UK
    7.1.6 Italy
    7.1.7 Russia
    7.2 Europe Natural Killer (NK) Cell Therapeutics by Type
    7.3 Europe Natural Killer (NK) Cell Therapeutics by Application
    7.4 Europe Natural Killer (NK) Cell Therapeutics by Company

    8 Asia Pacific
    8.1 Asia Pacific Natural Killer (NK) Cell Therapeutics by Countries
    8.1.1 Asia Pacific Natural Killer (NK) Cell Therapeutics Sales by Countries
    8.1.2 Asia Pacific Natural Killer (NK) Cell Therapeutics Revenue by Countries
    8.1.3 China
    8.1.4 Japan
    8.1.5 Korea
    8.1.6 India
    8.1.7 Australia
    8.1.8 Indonesia
    8.1.9 Malaysia
    8.1.10 Philippines
    8.1.11 Thailand
    8.1.12 Vietnam
    8.1.13 Singapore
    8.2 Asia Pacific Natural Killer (NK) Cell Therapeutics by Type
    8.3 Asia Pacific Natural Killer (NK) Cell Therapeutics by Application
    8.4 Asia Pacific Natural Killer (NK) Cell Therapeutics by Company

    9 Central & South America
    9.1 Central & South America Natural Killer (NK) Cell Therapeutics by Countries
    9.1.1 Central & South America Natural Killer (NK) Cell Therapeutics Sales by Countries
    9.1.2 Central & South America Natural Killer (NK) Cell Therapeutics Revenue by Countries
    9.1.3 Brazil
    9.2 Central & South America Natural Killer (NK) Cell Therapeutics by Type
    9.3 Central & South America Natural Killer (NK) Cell Therapeutics by Application
    9.4 Central & South America Natural Killer (NK) Cell Therapeutics by Company

    10 Middle East and Africa
    10.1 Middle East and Africa Natural Killer (NK) Cell Therapeutics by Countries
    10.1.1 Middle East and Africa Natural Killer (NK) Cell Therapeutics Sales by Countries
    10.1.2 Middle East and Africa Natural Killer (NK) Cell Therapeutics Revenue by Countries
    10.1.3 GCC Countries
    10.1.4 Turkey
    10.1.5 Egypt
    10.1.6 South Africa
    10.2 Middle East and Africa Natural Killer (NK) Cell Therapeutics by Type
    10.3 Middle East and Africa Natural Killer (NK) Cell Therapeutics by Application
    10.4 Middle East and Africa Natural Killer (NK) Cell Therapeutics by Company

    11 Company Profiles
    11.1 Chipscreen Biosciences (China)
    11.1.1 Chipscreen Biosciences (China) Company Details
    11.1.2 Company Description
    11.1.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.1.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.1.5 Recent Development
    11.2 Affimed NV (Netherlands)
    11.2.1 Affimed NV (Netherlands) Company Details
    11.2.2 Company Description
    11.2.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.2.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.2.5 Recent Development
    11.3 Altor BioScience Corporation (USA)
    11.3.1 Altor BioScience Corporation (USA) Company Details
    11.3.2 Company Description
    11.3.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.3.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.3.5 Recent Development
    11.4 Innate Pharma SA (France)
    11.4.1 Innate Pharma SA (France) Company Details
    11.4.2 Company Description
    11.4.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.4.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.4.5 Recent Development
    11.5 Takeda Pharmaceutical (Japan)
    11.5.1 Takeda Pharmaceutical (Japan) Company Details
    11.5.2 Company Description
    11.5.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.5.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.5.5 Recent Development
    11.6 Sorrento Therapeutics Inc. (USA)
    11.6.1 Sorrento Therapeutics Inc. (USA) Company Details
    11.6.2 Company Description
    11.6.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.6.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.6.5 Recent Development
    11.7 NantKwest Inc. (USA)
    11.7.1 NantKwest Inc. (USA) Company Details
    11.7.2 Company Description
    11.7.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.7.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.7.5 Recent Development
    11.8 Bristol-Myers Squibb (USA)
    11.8.1 Bristol-Myers Squibb (USA) Company Details
    11.8.2 Company Description
    11.8.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.8.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.8.5 Recent Development
    11.9 NKT Therapeutics (USA)
    11.9.1 NKT Therapeutics (USA) Company Details
    11.9.2 Company Description
    11.9.3 Sales, Revenue and Gross Margin of Natural Killer (NK) Cell Therapeutics
    11.9.4 Natural Killer (NK) Cell Therapeutics Product Description
    11.9.5 Recent Development

    12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    12.1 Market Opportunities and Drivers
    12.2 Market Challenges
    12.3 Market Risks/Restraints
    12.4 Key World Economic Indicators

    13 Value Chain and Sales Channels Analysis
    13.1 Value Chain Analysis
    13.1.1 Typical Suppliers of Key Natural Killer (NK) Cell Therapeutics Raw Material
    13.1.2 Natural Killer (NK) Cell Therapeutics Customers
    13.2 Sales Channels Analysis
    13.2.1 Sales Channels Analysis
    13.2.2 Distributors

    14 Research Findings and Conclusion

    15 Appendix
    15.1 Research Methodology
    15.1.1 Methodology/Research Approach
    15.1.1.1 Research Programs/Design
    15.1.1.2 Market Size Estimation
    15.1.1.3 Market Breakdown and Data Triangulation
    15.1.2 Data Source
    15.1.2.1 Secondary Sources
    15.1.2.2 Primary Sources
    15.2 Author Details
    15.3 Disclaimer



    About Decision Market Reports
    Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

    Contact Information:
    Gasper James,
    Decision Market Reports,
    304 S Jones Blvd,
    Las Vegas,
    NV 89107, USA
    Call: 1-800-526-8630 (Toll-Free)
    Email:sales@decisionmarketreports.com




    Gasper James
    +1-866-605-1052
    g.james @decisionmarketreports.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, November 28, 2018 ) “Global Medical Bed Market 2018” report provides information on grasping newer technologies and recent development made in Medical Bed & satisfies specialized and enterprise-wide statistical needs.

    This research report categorizes the global Medical Bed market by top players/brands, region, type and end user. This report also studies the global Medical Bed market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

    Download Free PDF Sample of Global Medical Bed Market 2018 report @ https://decisionmarketreports.com/request-sample?productID=858474

    The global Medical Bed market is valued at 1340 million US$ in 2017 and will reach 1390 million US$ by the end of 2025, growing at a CAGR of 0.4% during 2018-2025. The objectives of this study are to define, segment, and project the size of the Medical Bed market based on company, product type, end user and key regions.

    The following manufacturers are covered in this report, with sales, revenue, market share for each company:

    Hill-Rom Holdings, Inc.
    Invacare Corporation
    Drive Medical
    Stryker Corporation.
    ArjoHuntleigh
    Gendron Inc
    Graham Field Health Products, Inc.
    Hard Manufacturing Co
    Umano Medical
    Transfer Master
    American Medical Equipment (AME)
    ProBed Medical
    Market size by Product

    Long Term Care Bed
    Maternal Bed
    Critical Bed
    Medical Surgical Bed
    Others
    Market size by End User

    Household Medical Bed
    Hospital Medical Bed
    Others
    With the development of the medical equipment and various demands from the patient, there are coming more and more categories of multi-function and specialized medical beds. Medical Bed researched in this report includes: Med/Surg Hospital Bed; Home Care Bed; Long Term Care/Rehab Bed; Bariatric Bed; Critical Care Beds. In this report, we divide the medical beds into five types: Maternity Bed, Critical care bed, Medical surgical bed, Long term care bed and other; at the same time we divide the medical beds into three applications: Home care bed, Hospital bed and other.

    Over the long term, overall patient and provider demand for health care products and services will continue to grow as a result of a number of factors, including an aging population, longer life expectancies, and an increasing number of sicker patients across all care settings, including hospitals, extended care facilities and in the home.

    The monopoly power of the leader companies will enhance a lot .The Hill-Rom have made several recent acquisitions, most notably the acquisitions of Welch Allyn Holdings, Inc. (“Welch Allyn”), Trumpf Medical (“Trumpf”), and Virtus, Inc. (“Virtus”), and we plan to make additional acquisitions in the future.

    There are growing desire demand among developing countries to Invest in Health Care. While industry growth rates in more mature geographic regions such as western and northern Europe and Japan have moderated, in many other geographic markets, where the relative spending on health care is increasing, we expect long-term increasing demand for medical technologies. New hospital construction and hospital refurbishments are expected in regions such as Latin America, the Middle East and many parts of Asia. This could increase overall demand for our products and services.

    Access full report with TOC @ https://decisionmarketreports.com/market-reports/858474/global-medical-bed-market-2

    Acuities and Technological Impact is changing. As a result of the growing population of the elderly and obese, health care systems are challenged to treat rising incidences of complex diseases and conditions such as diabetes, congestive heart failure and respiratory disease.

    As a conclusion, there will be slow growth in the demands of the medical beds in North America, and the America and the Canada, especially America will control the whole North America market. Even the Mexico has a big population, there is nearly no players in medical beds industry, and the demand quantity is very small. The monopoly will make more barriers to the new players . And the technology will be the decisive factors to the stability of the developing of the players.

    Market size by Region

    North America
    United States
    Canada
    Mexico
    Asia-Pacific
    China
    India
    Japan
    South Korea
    Australia
    Indonesia
    Singapore
    Malaysia
    Philippines
    Thailand
    Vietnam
    Europe
    Germany
    France
    UK
    Italy
    Spain
    Russia
    Central & South America
    Brazil
    Rest of Central & South America
    Middle East & Africa
    GCC Countries
    Turkey
    Egypt
    South Africa
    Request Methodology for Global Medical Bed Market 2018 @ https://decisionmarketreports.com/request-methodolgy?productID=858474

    Table of Contents

    1 Study Coverage
    1.1 Medical Bed Product
    1.2 Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
    1.4.1 Global Medical Bed Market Size Growth Rate by Product
    1.4.2 Long Term Care Bed
    1.4.3 Maternal Bed
    1.4.4 Critical Bed
    1.4.5 Medical Surgical Bed
    1.4.6 Others
    1.5 Market by End User
    1.5.1 Global Medical Bed Market Size Growth Rate by End User
    1.5.2 Household Medical Bed
    1.5.3 Hospital Medical Bed
    1.5.4 Others
    1.6 Study Objectives
    1.7 Years Considered

    2 Executive Summary
    2.1 Global Medical Bed Market Size
    2.1.1 Global Medical Bed Revenue 2013-2025
    2.1.2 Global Medical Bed Sales 2013-2025
    2.2 Medical Bed Growth Rate by Regions
    2.2.1 Global Medical Bed Sales by Regions
    2.2.2 Global Medical Bed Revenue by Regions

    3 Breakdown Data by Manufacturers
    3.1 Medical Bed Sales by Manufacturers
    3.1.1 Medical Bed Sales by Manufacturers
    3.1.2 Medical Bed Sales Market Share by Manufacturers
    3.1.3 Global Medical Bed Market Concentration Ratio (CR5 and HHI)
    3.2 Medical Bed Revenue by Manufacturers
    3.2.1 Medical Bed Revenue by Manufacturers (2013-2018)
    3.2.2 Medical Bed Revenue Share by Manufacturers (2013-2018)
    3.3 Medical Bed Price by Manufacturers
    3.4 Medical Bed Manufacturing Base Distribution, Product Types
    3.4.1 Medical Bed Manufacturers Manufacturing Base Distribution, Headquarters
    3.4.2 Manufacturers Medical Bed Product Type
    3.4.3 Date of International Manufacturers Enter into Medical Bed Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product
    4.1 Global Medical Bed Sales by Product
    4.2 Global Medical Bed Revenue by Product
    4.3 Medical Bed Price by Product

    5 Breakdown Data by End User
    5.1 Overview
    5.2 Global Medical Bed Breakdown Data by End User

    6 North America
    6.1 North America Medical Bed by Countries
    6.1.1 North America Medical Bed Sales by Countries
    6.1.2 North America Medical Bed Revenue by Countries
    6.1.3 United States
    6.1.4 Canada
    6.1.5 Mexico
    6.2 North America Medical Bed by Product
    6.3 North America Medical Bed by End User

    7 Europe
    7.1 Europe Medical Bed by Countries
    7.1.1 Europe Medical Bed Sales by Countries
    7.1.2 Europe Medical Bed Revenue by Countries
    7.1.3 Germany
    7.1.4 France
    7.1.5 UK
    7.1.6 Italy
    7.1.7 Russia
    7.2 Europe Medical Bed by Product
    7.3 Europe Medical Bed by End User

    8 Asia Pacific
    8.1 Asia Pacific Medical Bed by Countries
    8.1.1 Asia Pacific Medical Bed Sales by Countries
    8.1.2 Asia Pacific Medical Bed Revenue by Countries
    8.1.3 China
    8.1.4 Japan
    8.1.5 Korea
    8.1.6 India
    8.1.7 Australia
    8.1.8 Indonesia
    8.1.9 Malaysia
    8.1.10 Philippines
    8.1.11 Thailand
    8.1.12 Vietnam
    8.1.13 Singapore
    8.2 Asia Pacific Medical Bed by Product
    8.3 Asia Pacific Medical Bed by End User

    9 Central & South America
    9.1 Central & South America Medical Bed by Countries
    9.1.1 Central & South America Medical Bed Sales by Countries
    9.1.2 Central & South America Medical Bed Revenue by Countries
    9.1.3 Brazil
    9.2 Central & South America Medical Bed by Product
    9.3 Central & South America Medical Bed by End User

    10 Middle East and Africa
    10.1 Middle East and Africa Medical Bed by Countries
    10.1.1 Middle East and Africa Medical Bed Sales by Countries
    10.1.2 Middle East and Africa Medical Bed Revenue by Countries
    10.1.3 GCC Countries
    10.1.4 Turkey
    10.1.5 Egypt
    10.1.6 South Africa
    10.2 Middle East and Africa Medical Bed by Product
    10.3 Middle East and Africa Medical Bed by End User

    11 Company Profiles
    11.1 Hill-Rom Holdings, Inc.
    11.1.1 Hill-Rom Holdings, Inc. Company Details
    11.1.2 Company Business Overview
    11.1.3 Hill-Rom Holdings, Inc. Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.1.4 Hill-Rom Holdings, Inc. Medical Bed Products Offered
    11.1.5 Hill-Rom Holdings, Inc. Recent Development
    11.2 Invacare Corporation
    11.2.1 Invacare Corporation Company Details
    11.2.2 Company Business Overview
    11.2.3 Invacare Corporation Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.2.4 Invacare Corporation Medical Bed Products Offered
    11.2.5 Invacare Corporation Recent Development
    11.3 Drive Medical
    11.3.1 Drive Medical Company Details
    11.3.2 Company Business Overview
    11.3.Drive Medical Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.3.4 Drive Medical Medical Bed Products Offered
    11.3.5 Drive Medical Recent Development
    11.4 Stryker Corporation.
    11.4.1 Stryker Corporation. Company Details
    11.4.2 Company Business Overview
    11.4.3 Stryker Corporation. Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.4.4 Stryker Corporation. Medical Bed Products Offered
    11.4.5 Stryker Corporation. Recent Development
    11.5 ArjoHuntleigh
    11.5.1 ArjoHuntleigh Company Details
    11.5.2 Company Business Overview
    11.5.3 ArjoHuntleigh Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.5.4 ArjoHuntleigh Medical Bed Products Offered
    11.5.5 ArjoHuntleigh Recent Development
    11.6 Gendron Inc
    11.6.1 Gendron Inc Company Details
    11.6.2 Company Business Overview
    11.6.3 Gendron Inc Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.6.4 Gendron Inc Medical Bed Products Offered
    11.6.5 Gendron Inc Recent Development
    11.7 Graham Field Health Products, Inc.
    11.7.1 Graham Field Health Products, Inc. Company Details
    11.7.2 Company Business Overview
    11.7.3 Graham Field Health Products, Inc. Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.7.4 Graham Field Health Products, Inc. Medical Bed Products Offered
    11.7.5 Graham Field Health Products, Inc. Recent Development
    11.8 Hard Manufacturing Co
    11.8.1 Hard Manufacturing Co Company Details
    11.8.2 Company Business Overview
    11.8.3 Hard Manufacturing Co Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.8.4 Hard Manufacturing Co Medical Bed Products Offered
    11.8.5 Hard Manufacturing Co Recent Development
    11.9 Umano Medical
    11.9.1 Umano Medical Company Details
    11.9.2 Company Business Overview
    11.9.3 Umano Medical Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.9.4 Umano Medical Medical Bed Products Offered
    11.9.5 Umano Medical Recent Development
    11.10 Transfer Master
    11.10.1 Transfer Master Company Details
    11.10.2 Company Business Overview
    11.10.3 Transfer Master Medical Bed Sales, Revenue and Gross Margin (2013-2018)
    11.10.4 Transfer Master Medical Bed Products Offered
    11.10.5 Transfer Master Recent Development
    11.11 American Medical Equipment (AME)
    11.12 ProBed Medical

    12 Future Forecast
    12.1 Medical Bed Market Forecast by Regions
    12.1.1 Global Medical Bed Sales Forecast by Regions 2018-2025
    12.1.2 Global Medical Bed Revenue Forecast by Regions 2018-2025
    12.2 Medical Bed Market Forecast by Product
    12.2.1 Global Medical Bed Sales Forecast by Product 2018-2025
    12.2.2 Global Medical Bed Revenue Forecast by Product 2018-2025
    12.3 Medical Bed Market Forecast by End User
    12.4 North America Medical Bed Forecast
    12.5 Europe Medical Bed Forecast
    12.6 Asia Pacific Medical Bed Forecast
    12.7 Central & South America Medical Bed Forecast
    12.8 Middle East and Africa Medical Bed Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    13.1 Market Opportunities and Drivers
    13.2 Market Challenges
    13.3 Market Risks/Restraints
    13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis
    14.1 Value Chain Analysis
    14.2 Medical Bed Customers
    14.3 Sales Channels Analysis
    14.3.1 Sales Channels
    14.3.2 Distributors

    15 Research Findings and Conclusion

    16 Appendix
    16.1 Research Methodology
    16.1.1 Methodology/Research Approach
    16.1.2 Data Source
    16.2 Author Details
    16.3 Disclaimer

    About Decision Market Reports
    Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

    Contact Information:
    Gasper James,
    Decision Market Reports,
    304 S Jones Blvd,
    Las Vegas,
    NV 89107, USA
    Call: 1-800-526-8630 (Toll-Free)
    Email:sales@decisionmarketreports.com




    Gasper James
    +1-866-605-1052
    g.james @decisionmarketreports.com

    Source: EmailWire.Com

older | 1 | .... | 1100 | 1101 | (Page 1102) | 1103 | 1104 | .... | 1118 | newer